Reapplix

medical devices

About

Reapplix is a Danish medtech company founded in 2008 that focuses on the biological treatment of diabetic foot ulcers. Its main product, the 3C Patch® System (also known as LeucoPatch®), is an innovative wound therapy made entirely from the patient's own blood components. This autologous patch is designed to stimulate healing in chronic diabetic foot ulcers by utilizing the body's natural healing abilities. The technology has been validated through clinical research, including a randomized controlled trial published in *The Lancet Diabetes & Endocrinology*, which showed improved healing outcomes compared to standard care. Reapplix has received FDA approval for its therapy, enhancing patient access in the United States. The company supports hospitals and wound clinics in implementing this therapy, aiming to improve patient outcomes and reduce healthcare costs associated with diabetic foot complications. Reapplix is actively expanding its presence in the US and European markets.

Technologies

OutlookMicrosoft Office 365ApacheGoogle Font APIMobile FriendlyreCAPTCHAGoogle Maps (Non Paid Users)VimeoGoogle AnalyticsGoogle Tag ManagerWordPress.orgYouTubeGoogle MapsDomoSisenseRemoteKNIME

Keywords

advanced wound caremedical devicewound therapyprpmedical equipment manufacturingmedical devicesblood cell therapy for woundsblood-based wound therapygrowth factorsblood coagulation technologyhealthcareblood cell concentrate devicewound healing clinical trialblood component separationpersonalized blood patch3c patch systemblood coagulation devicewound care innovationblood cell concentrateblood derived biomaterialsregenerative medicine solutionswound careblood cell separationwound healingblood component processingblood sample centrifugeblood component therapy deviceactive blood cellsmedical equipment and supplies manufacturingwound healing products

Location

45 Blokken, Birkerod, Capital Region of Denmark, Denmark, 3460

Related Companies

Companies in the same industry